S Nicole Culos-Reed1,2,3, Heather J Leach4, Lauren C Capozzi5,6, Jacob Easaw6, Neil Eves7, Guillaume Y Millet5. 1. Faculty of Kinesiology, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N-1N4, Canada. nculosre@ucalgary.ca. 2. Department of Psychosocial Resources, Tom Baker Cancer Centre, Alberta Health Services, Calgary, AB, Canada. nculosre@ucalgary.ca. 3. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. nculosre@ucalgary.ca. 4. Department of Health and Exercise Science, Colorado State University, Fort Collins, CO, USA. 5. Faculty of Kinesiology, University of Calgary, 2500 University Dr. NW, Calgary, AB, T2N-1N4, Canada. 6. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 7. School of Health and Exercise Science, University of British Columbia - Okanagan, Kelowna, BC, Canada.
Abstract
PURPOSE: Exercise has numerous benefits for cancer survivors, but very limited research to date has exclusively examined brain cancer patients, specifically those diagnosed with high-grade glioma (HGG). This study examined (1) the feasibility of recruiting HGG patients to an exercise-based study and performing fitness assessments; (2) exercise counseling and programming preferences; and (3) associations between fitness, physical activity (PA), and quality of life (QOL). METHODS: Participants completed assessments prior to starting Temozolamide chemotherapy with radiation (T1), at 2 months and 8 months. Fitness was measured with an incremental cycling exercise test to volitional exhaustion (VO2peak) and hand grip dynamometry. The Godin leisure time questionnaire measured PA and the functional assessment for cancer therapy, brain cancer module (FACT-Br) measured QOL. RESULTS: Of the 35 approached, N = 16 participated. Due to safety concerns, the aerobic fitness test protocol was altered. Participants preferred to exercise during treatment, alone and unsupervised, at home, and at a moderate intensity. Few participants (<25%) met guidelines for PA at any time point. At T1, aerobic capacity was associated with the FACT Trial Outcome Index (TOI) (r = 0.619, p < 0.05). At 2 months, PA minutes were associated with FACT-TOI (r = 0.653, p = 0.057), FACT-G (r = 0.711, p < 0.05), and FACT-Br scores (r = 0.722, p < 0.05). CONCLUSIONS: Recruitment rate was similar to a previous study in HGG populations, but study completion rate was lower. Most exercise counseling and programming preferences were similar to previous brain cancer patients. Assessing aerobic fitness to VO2peak was not feasible. Aerobic fitness and PA were positively associated with QOL.
PURPOSE: Exercise has numerous benefits for cancer survivors, but very limited research to date has exclusively examined brain cancerpatients, specifically those diagnosed with high-grade glioma (HGG). This study examined (1) the feasibility of recruiting HGG patients to an exercise-based study and performing fitness assessments; (2) exercise counseling and programming preferences; and (3) associations between fitness, physical activity (PA), and quality of life (QOL). METHODS:Participants completed assessments prior to starting Temozolamide chemotherapy with radiation (T1), at 2 months and 8 months. Fitness was measured with an incremental cycling exercise test to volitional exhaustion (VO2peak) and hand grip dynamometry. The Godin leisure time questionnaire measured PA and the functional assessment for cancer therapy, brain cancer module (FACT-Br) measured QOL. RESULTS: Of the 35 approached, N = 16 participated. Due to safety concerns, the aerobic fitness test protocol was altered. Participants preferred to exercise during treatment, alone and unsupervised, at home, and at a moderate intensity. Few participants (<25%) met guidelines for PA at any time point. At T1, aerobic capacity was associated with the FACT Trial Outcome Index (TOI) (r = 0.619, p < 0.05). At 2 months, PA minutes were associated with FACT-TOI (r = 0.653, p = 0.057), FACT-G (r = 0.711, p < 0.05), and FACT-Br scores (r = 0.722, p < 0.05). CONCLUSIONS: Recruitment rate was similar to a previous study in HGG populations, but study completion rate was lower. Most exercise counseling and programming preferences were similar to previous brain cancerpatients. Assessing aerobic fitness to VO2peak was not feasible. Aerobic fitness and PA were positively associated with QOL.
Entities:
Keywords:
Exercise; Glioma; Quality of life; Surveys and questionnaires
Authors: Kathryn H Schmitz; Kerry S Courneya; Charles Matthews; Wendy Demark-Wahnefried; Daniel A Galvão; Bernardine M Pinto; Melinda L Irwin; Kathleen Y Wolin; Roanne J Segal; Alejandro Lucia; Carole M Schneider; Vivian E von Gruenigen; Anna L Schwartz Journal: Med Sci Sports Exerc Date: 2010-07 Impact factor: 5.411
Authors: Lee W Jones; Bebe Guill; Stephen T Keir; Karen Carter; Henry S Friedman; Darell D Bigner; David A Reardon Journal: Support Care Cancer Date: 2006-07-04 Impact factor: 3.603
Authors: Lee W Jones; Marina Mourtzakis; Katherine B Peters; Allan H Friedman; Miranda J West; Stephanie K Mabe; William E Kraus; Henry S Friedman; David A Reardon Journal: Oncologist Date: 2010-05-18
Authors: Jeffrey A Meyerhardt; Edward L Giovannucci; Michelle D Holmes; Andrew T Chan; Jennifer A Chan; Graham A Colditz; Charles S Fuchs Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: Katherine B Peters; Miranda J West; Whitney E Hornsby; Emily Waner; April D Coan; Frances McSherry; James E Herndon; Henry S Friedman; Annick Desjardins; Lee W Jones Journal: J Neurooncol Date: 2014-08-13 Impact factor: 4.130
Authors: Emily Ruden; David A Reardon; April D Coan; James E Herndon; Whitney E Hornsby; Miranda West; Diane R Fels; Annick Desjardins; James J Vredenburgh; Emily Waner; Allan H Friedman; Henry S Friedman; Katherine B Peters; Lee W Jones Journal: J Clin Oncol Date: 2011-06-20 Impact factor: 44.544
Authors: Lee W Jones; Bebe Guill; Stephen T Keir; Karen Carter B S; Henry S Friedman; Darrell D Bigner; David A Reardon Journal: Cancer Date: 2006-05-15 Impact factor: 6.860
Authors: Karin Gehring; Corelien Jj Kloek; Neil K Aaronson; Kasper W Janssen; Lee W Jones; Margriet M Sitskoorn; Martijn M Stuiver Journal: Clin Rehabil Date: 2017-09-08 Impact factor: 3.477
Authors: Alice Avancini; Ilaria Trestini; Daniela Tregnago; Lorenzo Belluomini; Marco Sposito; Jessica Insolda; Federico Schena; Michele Milella; Sara Pilotto Journal: J Cancer Res Clin Oncol Date: 2022-08-09 Impact factor: 4.322
Authors: Isabelle Schaefer; Nicole Heneka; Tim Luckett; Meera R Agar; Suzanne K Chambers; David C Currow; Georgia Halkett; Domenica Disalvo; Ingrid Amgarth-Duff; Cleola Anderiesz; Jane L Phillips Journal: BMC Palliat Care Date: 2021-01-23 Impact factor: 3.234
Authors: Carolina X Sandler; Misa Matsuyama; Tamara L Jones; John Bashford; Danette Langbecker; Sandra C Hayes Journal: J Neurooncol Date: 2021-04-28 Impact factor: 4.130
Authors: Karin Gehring; Martijn M Stuiver; Eva Visser; Corelien Kloek; Martin van den Bent; Monique Hanse; Cees Tijssen; Geert-Jan Rutten; Martin J B Taphoorn; Neil K Aaronson; Margriet M Sitskoorn Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300